Anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-02. Anything still debated is marked as such rather than presented as settled.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
In the 1980s and 1990s, Athene Donald's polymer physics lab in Cambridge extensively characterised phase transitions / phase separation of starch granules from the cytoplasm of plant cells, which behave as liquid crystals. In 1991, Pierre-Gilles de Gennes received the Nobel Prize in Physics for developing a generalized theory of phase transitions with particular applications to describing ordering and phase transitions in polymers. Unfortunately, de Gennes wrote in Nature that polymers should be distinguished from other types of colloids, even though they can display similar clustering and phase separation behaviour, a stance that has been reflected in the reduced usage of the term colloid to describe the higher-order association behaviour of biopolymers in modern cell biology and molecular self-assembly.
Metabolism-first hypothesis suggests that autocatalytic networks of metabolic reactions were the first forms of life. This is an alternative hypothesis to RNA-world, which is a genes-first hypothesis. It was first proposed by Martynas Ycas in 1955. A lot of recent work in this area is focused in computational modeling of theoretical prebiotic networks. Metabolism-first proponents postulate that replication and genetic machinery could not arise without the accumulation of the molecules needed for replication. Alone, simple connections between prebiotic synthesis reactions could form key organic molecules and once encapsulated by a membrane would constitute the first cells. These reactions could be catalyzed by various inorganic molecules or ions and stabilized by solid surfaces. Molecular self-replicators and enzymes would emerge later, with these future metabolisms better resembling modern metabolism. One critique for the metabolism-first hypothesis for abiogenesis is they would also need self-replicating abilities with a high degree of fidelity. If not, the chemical networks with greater fitness in early Earth would not be preserved. There is limited experimental evidence for these theories, so additional exploration in this area is needed to determine the feasibility of a metabolism-first origins of life.
== History == In a Phase III multicenter clinical trial including 237 patients with hyperkalemia under RAAS inhibitor treatment, 76% of participants reached normal serum potassium levels within four weeks. After subsequent randomization of 107 responders into a group receiving continued patiromer treatment and a placebo group, re-occurrence of hyperkalemia was 15% versus 60%, respectively.
Etilefrine, sold under the brand name Effortil among others, is a sympathomimetic medication used as an antihypotensive agent to treat orthostatic hypotension. It is usually used by mouth, but is also available as an injectable. Side effects of etilefrine include nausea, tremors, and palpitations, among others. Etilefrine is an agonist of the α- and β-adrenergic receptors. It is a substituted phenethylamine and is related to epinephrine, phenylephrine, and norfenefrine. Etilefrine was first described and introduced for medical use by 1949.
Sources: en.wikipedia.org
During World War II, Germany used submarines to devastating effect in the Battle of the Atlantic, where it attempted to cut Britain's supply routes by sinking more merchant ships than Britain could replace. These merchant ships were vital to supply Britain's population with food, industry with raw material, and armed forces with fuel and armaments. Although the U-boats had been updated in the interwar years, the major innovation was improved communications, encrypted using the Enigma cipher machine. This allowed for mass-attack naval tactics (Rudeltaktik, commonly known as "wolfpack"), which ultimately ceased to be effective when the U-boat's Enigma was cracked. By the end of the war, almost 3,000 Allied ships (175 warships, 2,825 merchantmen) had been sunk by U-boats. Although successful early in the war, Germany's U-boat fleet suffered heavy casualties, losing 793 U-boats and about 28,000 submariners out of 41,000, a casualty rate of about 70%. The Imperial Japanese Navy operated the most varied fleet of submarines of any navy, including Kaiten crewed torpedoes, midget submarines (Type A Ko-hyoteki and Kairyu classes), medium-range submarines, purpose-built supply submarines and long-range fleet submarines. They also had submarines with the highest submerged speeds during World War II (I-201-class submarines) and submarines that could carry multiple aircraft (I-400-class submarines). They were also equipped with one of the most advanced torpedoes of the conflict, the oxygen-propelled Type 95.
The composition and rate of CSF generation are influenced by hormones and the content and pressure of blood and CSF. For example, when CSF pressure is higher, there is less of a pressure difference between the capillary blood in choroid plexuses and CSF, decreasing the rate at which fluids move into the choroid plexus and CSF generation. The autonomic nervous system influences choroid plexus CSF secretion, with activation of the sympathetic nervous system decreasing secretion and the parasympathetic nervous system increasing it. Changes in the pH of the blood can affect the activity of carbonic anhydrase, and some drugs (such as furosemide, acting on the Na-K-Cl cotransporter) have the potential to impact membrane channels.
When an 235U atom captures a neutron, it is converted to an excited state of 236U. About 85.5% of the excited 236U nuclei undergo fission, but the remainder decay to the ground state of 236U by emitting gamma radiation. Further neutron capture forms 237U which has a half-life of 7 days and quickly decays to 237Np through beta decay. During beta decay, the excited 237U emits an electron, while the atomic weak interaction converts a neutron to a proton, thus creating 237Np.
=== PPAR-delta agonists === PPARδ (delta) is the main target of a research chemical named GW501516. It has been shown that agonism of PPARδ changes the body's fuel preference from glucose to lipids. In August 2024, seladelpar became the first PPARδ agonist to be approved for clinical use.
According to one cable, Deputy Assistant Secretary of State for European and Eurasian Affairs Matthew Bryza "has been clear with Saakashvili: if Georgia uses force or stumbles into a conflict, Saakashvili will find himself alone, blamed by the international community for recklessness." Tefft was told by an Abkhaz official in 2007 that there had been an attempt by Russia to coerce Abkhaz leader Sergei Bagapsh into launching a military operation against Georgia in 2006. President of France Nicolas Sarkozy assured Putin in October 2007 that France did not support Georgia's NATO membership while telling Saakashvili the opposite. In January 2008, the French government was not enthusiastic about Ukraine's plans to join NATO.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.